Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human CD14 Protein, His tag, 2x500 µg  

Recombinant human CD14 Protein, His tag, 2x500 µg

Recombinant human CD14 (Thr20-Cys352), produced in human 293 cells (HEK293), His tag

Synonym
Recombinant human protein, CD14, CD-14

More details

CD4-H5228-1K

Availability: within 7 days

2 160,00 €

Background
Cluster of differentiation 14 (CD14), is a cell surface glycoprotein, and is a is a component of the innate immune system. CD14 is a myelomonocytic differentiation antigen preferentially expressed on monocytes, macrophages, and activated granulocytes. CD14 exists in two forms. Either it is anchored into the membrane by a glycosylphosphatidylinositol tail (mCD14) or it appears in a soluble form (sCD14). Soluble CD14 either appears after shedding of mCD14 (48 kDa) or is directly secreted from intracellular vesicles (56 kDa). CD14 acts as a co-receptor (along with the Toll-like receptor TLR 4 and MD-2) for the detection of bacterial lipopolysaccharide (LPS). CD14 can bind LPS only in the presence of lipopolysaccharide-binding protein (LBP). CD14 has been proposed to be involved in various biological processes, including transportation of other lipids, cell-cell interaction during different immune responses, as well as recognition of apoptotic cells. Although LPS is considered its main ligand, CD14 also recognizes other pathogen-associated molecular patterns. CD14+ cells are monocytes that can differentiate into a host of different cells. CD14 has been shown to interact with Lipopolysaccharide-binding protein. 

Source
Recombinant human CD14 (rhCD14) Thr20-Cys352 (Accession # AAH10507) was produced in human 293 cells (HEK293)

Molecular Characterization
rhCD14, contains eleven leucine-rich repeats regions and five glycosylation sites, and fused with 6×his tag at the C-terminal and has a calculated MW of 36.6 kDa expressed. The predicted N-terminal is Thr20. Due to different glycosylation, DTT-reduced protein migrates as 45 -50 kDa polypeptide.

Endotoxin
Less than 1.0 EU per 1 μg of the rhCD14 by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Supplied as a 0.22 μm filtered solution in PBS, pH 7.4 and delivered as liquid formulation or lyophilized powder. Normally mannitol or trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4C-8C); After reconstitution under sterile conditions for 1 month (4C-8C) or 3 months (-20C to -70C). 

Bioactivity
N/A

References

(1) Kirkland TN, Viriyakosol S, et al., 1998, Prog. Clin. Biol. Res. 397: 79–87.
(2) Kitchens RL., 2000, Chem. Immunol.. Chemical Immunology and Allergy 74: 61–82.
(3) Tapping RI, Tobias PS., 2000, Chem. Immunol.. Chemical Immunology and Allergy 74: 108–21.
(4) Thomas, Celestine J., et al., 2002, FEBS Lett. (Netherlands) 531 (2): 184–8.
(5) Yu B, Wright S D., 1995, J. Inflamm. (UNITED STATES) 45 (2): 115–25.